evekhm/cms_iom_500 huggingface dataset:
(Medicare Claims Processing Manual)
Participating CAP physicians will continue to use ASP NOC codes when billing for NOC drugs that are not included in the CAP category they have chosen.  Participating CAP physicians are required to obtain all CAP drugs from the approved CAP vendor including any drugs added to the CAP drug list under this process, unless medical necessity requires the use of a formulation not supplied by the vendor.   100.8.3.1 - Editing for CAP NOC Drugs  (Rev. 3721, Issued: 02- 24-17, Effective: 05 -25-17, Implementation: 05- 25-17)  Should the A/B MAC (B) receive a CAP NOC code, but the description does not match a CAP NOC drug on the approved list, the contractor shall use the following remittance advice messages and associated codes when rejecting/denying claims under this policy. This CARC/RARC combination is compliant with CAQH CORE Business Scenario Two.   Group Code: CO  CARC: 16  RARC: N350  MSN: N/A  Should a non- CAP physician submit the CAP NOC code, the contractor shall use the following remittance advice messages and associated codes when rejecting/denying claims under this policy. This CARC/RARC combination is compliant with CAQH CORE Business Scen ario Two.   Group Code: CO  CARC: 16  RARC: N56  MSN: N/A  Should a CAP physician submit a J NOC code with a description of a CAP approved NOC drug, the contractor shall use the following remittance advice messages and associated codes when rejecting/denying claims under this policy. This CARC/RARC combination is compliant with CAQH CORE Business Scenario Two.   Group Code: CO  CARC: 16  RARC: N56  MSN: N/A  100.9 - Non-Participating Physicians Who Elect the CAP   (Rev. 866, Issued: 02- 17-06, Effective: 07 -01-06, Implementation: 07- 03-06)  Participating CAP physicians must appeal drug administration denials.  For a non-participating physician that elects to participate in the CAP, he or she must agree to accept assignment for all CAP drug administration charges to allow for the Medicare bene ficiarys and approved CAP vendors appeal rights.
(Medicare Claims Processing Manual)
A/B MACs (B) shall pay all HCPCS codes that provide payment for the administration of CAP drugs on an assigned basis.  101 - The Competitive Acquisition Program (CAP) for Drugs and Instructions on Special CAP Appeals Requirements and Delivery of Dispute Resolution Services  (Rev. 1076, Issued:  10- 13-2006; Effective:  07- 01-06; Implementation:  11- 13-06)  All appeals of denied CAP claims will be processed by the local A/B MAC (B).  This includes an appeal for the denial of an approved CAP vendors drug product claim.  This break from the traditional administrative appeals process is necessitated by the arrangement whereby the CAP designated A/B MAC (B) pays the approved CAP vendor claim only after a match is found in the central claims processing system indicating the corresponding partici pating CAP physicians drug administration claim was paid by the local A/B MAC (B).  As a result, the only appealable issues attach to the decision of the local A/B MAC (B).
(Medicare Claims Processing Manual)
The CAP claims processing arrangement departs from the standard Part B claims processing routine.  The A/B MAC (B) will make an initial determination on whether the participating CAP physicians claim for drug administration is payable by applying local coverage determinations (LCDs) to the administration and to the drugs billed as no- pay on the claim.  If the A/B MAC (B) finds the no- pay or administration lines are contrary to the LCDs, it will deny the administration and pass on a non- approved indicator on the no-pay lines.  The A/B MAC (B) sends a pay process indicator to CWF for each of the no-pay lines.  When the designated A/B MAC (B) enters the vendor claim into the system, CWF looks for a match.  When CWF goes to find the match, it will not match aga inst non-approved lines.  If it finds a match among the approved lines, then it lets the designated A/B MAC (B) know and the claim is paid.  If it doesnt find a match, the claim recycles for 90 days.  Periodically during the 90 days, the designated A/B MA C (B) looks for a match again.  If it finds one, the claim pays.  If after 90 days it doesn't find a match, then the claim denies.  The A/B MAC (B) will notify CWF whether the approved CAP vendors claim for the drug is payable.  If the vendors claim is not payable because of a determination of the A/B MAC (B), then the designated A/B MAC (B) will be notified.  In turn, the designated A/B MAC (B) will deny the approved CAP vendors claim.  The claims processing requirements for this process have been descr ibed in previous CAP Change Requests.  Because the A/B MAC (B)s initial determination on the drug administration claim decides the outcome of the of the approved CAP vendors drug product claim, CMS  interprets the initial determination to be an initial determination of the approved CAP vendors drug product claim for the purposes of the Part B appeals regulations found at 42 CFR 405.801.  Accordingly, the approved CAP vendor shall not file its appeal with the CAP designated A/B MAC (B).  Rather, the approved CAP vendor shall file its appeal with the
(Medicare Claims Processing Manual)
the Part B appeals regulations found at 42 CFR 405.801.  Accordingly, the approved CAP vendor shall not file its appeal with the CAP designated A/B MAC (B).  Rather, the approved CAP vendor shall file its appeal with the A/B MAC (B), with one exception.
(Medicare Claims Processing Manual)
That exception is the case where the approved CAP vendors drug product claim was denied because there was no matching claim filed by the participating CAP physician after 90 days of recycling.  In this instance, the designated A/B MAC (B) will deny the approved CAP vendors drug product claim and suppress appeal rights.  The remittance notice will instruct the approved CAP vendor that it may request a reopening.  Upon receipt of a reopening request, the designated A/B MAC (B) will contact the participating CAP physician and request that he or she fulfill his or her CAP participation agreement by filing the drug administration claim.  If the participating CAP physician does not follow through as required, then the designated A/B MAC (B) will initiate the dis pute resolution track discussed below.  In the role of the furnishing Medicare supplier, the approved CAP vendor is a party to any appeal of a denied drug administration claim filed by a participating CAP physician with the A/B MAC (B).  The balance of the rules pertaining to the A/B MAC (B)s adjudication of Part B appeals applies (See Pub. 100- 04, Chapter 29), with the following exceptions:   a) The A/B MAC (B) will check for duplicate appeals.  If the participating CAP physician and the approved CAP vendor filed independent appeals connected with the same service, then the A/B MAC (B) will merge the two files.   b) The A/B MAC (B) will ensure the approved CAP vendor is copied on all correspondence connected with the participating CAP physicians appeal of the denied drug administration claim.  101.1 - Dispute Resolution Services for Vendors (Rev. 1076, Issued:  10- 13-2006; Effective:  07- 01-06; Implementation:  11- 13-06)  The CAP designated A/B MAC (B) has responsibility to deliver dispute resolution services to the approved CAP vendor when the approved CAP vendors drug product claims are not paid because the participating CAP physician has either failed to file a payable drug administration claim or has failed to file a successful appeal of the denie d drug administration claim.   The approved CAP vendor may file its drug product claim on the day it delivers the drug to the participating CAP physician.  The participating CAP physician is contractually obligated to file his or her CAP drug administration claim within 14 days of admin istering the drug.
(Medicare Claims Processing Manual)
The approved CAP vendor may determine its own threshold for financial exposure.  If the approved CAP vendor does not receive payment within 14 days, then the approved CAP vendor may request assistance from the CAP designated A/B MAC (B) in encouraging the participating CAP physician to fulfill his or her contractual obligations.  If the CAP designated A/B MAC (B)s dispute resolution services do not yield adequate results for the approved CAP vendor, then the approved CAP vendor may request that the CAP des ignated A/B MAC (B) investigate the participating CAP physicians performance and recommend that the participating CAP physicians CAP election agreement be terminated.  If the CAP designated A/B MAC (B) does recommend termination, then a suspension, heari ng, and final termination process set forth in 42 CFR 414.916 will be employed by CMS.   101.2 - Dispute Resolution Services for Physicians (Rev. 1076, Issued:  10- 13-2006; Effective:  07- 01-06; Implementation:  11- 13-06)  If a participating CAP physician has an issue concerning the quality or safety of the services and/or drug delivered by the approved CAP vendor, then the participating CAP physician should address that issue through the approved CAP vendors grievance process.  If the participating CAP physician is not satisfied with the results of the approved CAP vendors grievance process, then the participating physician may ask the CAP designated A/B MAC (B) to review the situation and encourage the approved CAP vendor  to comply with its contractual obligations.  If the approved CAP vendor refuses to comply with its contractual CAP obligations, then the CAP designated A/B MAC (B) may recommend to CMS that the approved CAP vendors participation in CAP be terminated.  If  the CAP designated A/B MAC (B) does recommend termination, then a suspension, hearing, and final termination process set forth in 42 CFR 414.917 will be employed by CMS.  101.3 - Dispute Resolution Services for Beneficiaries  (Rev. 1076, Issued:  10- 13-2006; Effective:  07- 01-06; Implementation:  11- 13-06)
(Medicare Claims Processing Manual)
The approved CAP vendor is not permitted to bill the beneficiary for any coinsurance or deductible until the approved CAP vendors drug product claim has been paid by the designated A/B MAC (B).  If the approved CAP vendor does bill the beneficiary before payment on the drug claim has been received, or if the approved CAP vendor bills the beneficiary too much after the drug product claim has been paid, then the beneficiary may use the approved CAP vendors grievance process to challenge the inappropriate billing.  If the approved CAP vendors grievance process does not yield satisfactory results for the beneficiary, then the beneficiary may ask the CAP designated A/B MAC (B) to counsel the approved CAP vendor on its contractual CAP obligations.  Transmittals Issued for this Chapter  Rev #  Issue Date  Subject  Impl Date  CR#  R12201CP  08/10/2023 Annual Clotting Factor Furnishing Fee Update 2024  01/02/2024 13313 R12067CP  06/02/2023 New Claims Modifier Requirement for Drugs and Biologicals from a Single -Dose Container or Single -Use Package  07/03/2023 13056 R12013CP  05/02/2023 Inflation Reduction Act Section 11407: Limitations on Monthly Coinsurance and Adjustments to Supplier Payment Under Medicare Part B for Insulin Furnished Through Durable Medical Equipment (DME)  IMPLEMENTATION NO LONGER SENSITIVE  07/03/2023 13014 R11917CP  03/21/2023 Inflation Reduction Act Section 11407: Limitations on Monthly Coinsurance and Adjustments to Supplier Payment Under Medicare Part B for Insulin Furnished Through Durable Medical Equipment (DME)  IMPLEMENTATION-  Rescinded and replaced by Transmittal  12013 07/03/2023 13014 R11834CP  02/02/2023 Inflation Reduction Act Section 11407: Limitations on Monthly Coinsurance and Adjustments to Supplier Payment Under Medicare Part B for Insulin Furnished Through Durable Medical Equipment (DME)  IMPLEMENTATION  NO LONGER SENSITIVE - Rescinded and replaced by Transmittal  11917 07/03/2023 13014 R11764CP  12/22/2022 New Medicare Part B Immunosuppressant Drug Benefit (PBID)  Implementation  01/03/2023 12804 R11646CP  10/19/2022 New Medicare Part
(Medicare Claims Processing Manual)
12/22/2022 New Medicare Part B Immunosuppressant Drug Benefit (PBID)  Implementation  01/03/2023 12804 R11646CP  10/19/2022 New Medicare Part B Immunosuppressant Drug Benefit (PBID)  Implementation  - Rescinded and replaced by Transmittal 11764 01/03/2023 12804 R11596CP  09/13/2022 Annual Clotting Factor Furnishing Fee 01/03/2023 12860  Rev #  Issue Date  Subject  Impl Date  CR#  Update 2023  R11567CP  08/18/2022 Annual Clotting Factor Furnishing Fee Update 2023- Rescinded and replaced by Transmittal 11596 01/03/2023 12860 R11427CP  05/20/2022 Claims Processing Manual Update -  Pub. 100.04 for Elimination of Certificates of Medical Necessity (CMNs) and Durable Medical Equipment Forms (DIFs)  01/03/2023 12734 R11414CP  05/12/2022 Claims Processing Manual Update -  Pub. 100.04 for Elimination of Certificates of Medical Necessity (CMNs) and Durable Medical Equipment Forms (DIFs) -  Rescinded and replaced by Transmittal 11427 06/13/2022 12734 R11140CP  12/02/2021 Update to the Internet Only Manual (IOM) Publication 100- 04, Chapters 3 and 17 01/04/2022 12525 R10329CP  08/28/2020 Annual Clotting Factor Furnishing Fee Update 2021  01/04/2021 11932 R10236CP  07/31/2020 Update to the IOM Publication (Pub) 100-04, Medicare Claims Processing Manual, Chapters 1, 6, 8, 17, 20, 22, 24, and 31 Referencing the Active Universal Resource Locators (URLs) for the Washington Publishing Company (WPC) and the ASC X12 Organizations, and Updates to the HIPAA Eligibility Transaction System (HETS)  08/31/2020 11857 R4384CP  08/30/2019 Annual Clotting Factor Furnishing Fee Update 2020  01/06/2020 11435 R4233CP  02/08/2019 Update to Publication (Pub.) 100- 04 Chapters 4 and 17 to Provide Language -Only Changes for the New Medicare Card Project
(Medicare Claims Processing Manual)
Factor Furnishing Fee Update 2020  01/06/2020 11435 R4233CP  02/08/2019 Update to Publication (Pub.) 100- 04 Chapters 4 and 17 to Provide Language -Only Changes for the New Medicare Card Project  03/12/2019 11084 R4204CP  01/17/2019 January 2019 Update of the Hospital Outpatient Prospective Payment System (OPPS)  01/07/2019 11099  Rev #  Issue Date  Subject  Impl Date  CR#  R4186CP  12/31/2018 January 2019 Update of the Hospital Outpatient Prospective Payment System (OPPS)  Rescinded and replaced by Transmittal 4204  01/07/2019 11099 R4128CP  09/07/2018 Annual Clotting Factor Furnishing Fee Update 2019  01/07/2019 10918 R3932CP  12/08/2017 Special Requirements for Immunosuppressive Drugs  03/09/2018 10370 R3941CP  12/22/2017 January 2018 Update of the Hospital Outpatient Prospective Payment System (OPPS)  01/02/2018 10417 R3862CP  09/15/2017 Annual Clotting Factor Furnishing Fee Update 2018  01/02/2018 10254 R3856CP  09/01/2017 Clarification of the Billing of Immunosuppressive Drugs
(Medicare Claims Processing Manual)
10/02/2017 10235 R3721CP  02/24/2017 Updates to Pub. 100- 04, Chapters 12, 17 and 23 to Correct Remittance Advice Messages  05/25/2017 9906 R3607CP  08/26/2016 Annual Clotting Factor Furnishing Fee Update 2017  01/03/2017 9759 R3538CP  06/09/2016 JW Modifier: Drug Amount Discarded/Not Administered to Any Patient  01/03/2017 9603 R3530CP  05/24/2016 JW Modifier: Drug Amount Discarded/Not Administered to Any Patient -  Rescinded and replaced by Transmittal 3538  07/05/2016 9603 R3508CP  04/29/2016 JW Modifier: Drug Amount Discarded/Not Administered to Any Patient  Rescinded and replaced by Transmittal 3530  07/05/2016 9603 R3340CP  08/21/2015 Annual Clotting Factor Furnishing Fee Update 2016  01/04/2016 9295  Rev #  Issue Date  Subject  Impl Date  CR#  R3292CP  07/10/2015 Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes -  July 2015 Update  07/06/2015 9167 R3254CP  05/08/2015 Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes -  July 2015 Update  07/06/2015 9167 R3085CP  10/03/2014 Update to Pub. 100- 04, Chapter 17 to Provide Language -Only Changes for Updating ICD -10 and ASC X12 11/04/2014 8647 R3055CP  08/29/2014 Annual Clotting Factor Furnishing Fee Update 2015  01/05/2015 8891 R2931CP  04/15/2014 Aprepitant for Chemotherapy Induced Emesis  07/07/2014 8418 R2903CP  03/11/2014 April Update of the Hospital Outpatient Prospective Payment System (OPPS)  04/07/2014 8653 R2894CP  02/28/2014 April Update of the Hospital Outpatient Prospective Payment System (OPPS)  Rescinded and replaced by Transmittal 2903 04/07/2014 8653 R2883CP  02/21/2014 Aprepitant for Chemotherapy Induced Emesis  Rescinded and replaced by Transmittal 2931
(Medicare Claims Processing Manual)
 Rescinded and replaced by Transmittal 2903 04/07/2014 8653 R2883CP  02/21/2014 Aprepitant for Chemotherapy Induced Emesis  Rescinded and replaced by Transmittal 2931  07/07/2014 8418 R2760CP  08/09/2013 Annual Clotting Factor Furnishing Fee Update 2014  01/06/2014 8423 R2554CP  09/28/2012 Annual Clotting Factor Furnishing Fee Update 2013  01/07/2013 8049 R2437CP  04/04/2012 Pharmacy Billing for Drugs Provided Incident to a Physician Service (This CR rescinds and fully replaces CR 7109)  01/01/2013 7397 R2424CP  03/16/2012 Influenza Virus Vaccine Annual Payment Limit Effective Date  08/01/2012 7741  Rev #  Issue Date  Subject  Impl Date  CR#  R2368CP  12/16/2011 Pharmacy Billing for Drugs Provided Incident to a Physician Service (This CR rescinds and fully replaces CR 7109)  Rescinded and replaced by Transmittal 2437 01/01/2013 7397 R2312CP  09/23/2011 Pharmacy Billing for Drugs Provided Incident to a Physician Service (This CR rescinds and fully replaces CR 7109)  Rescinded and replaced by Transmittal 2368 10/01/2011 7397 R2279CP  08/19/2011 Annual Clotting Factor Furnishing Fee Update 2012  01/03/2012 7543 R2271CP  08/05/2011 Pharmacy Billing for Drugs Provided Incident to a Physician Service (This CR rescinds and fully replaces CR 7109)  Rescinded and replaced by Transmittal 2312 10/01/2011 7397 R2251CP  07/01/2011 Pharmacy Billing for Drugs Provided Incident to a Physician Service (This CR rescinds and fully replaces CR 7109)  rescinded and replaced by Transmittal 2271 08/15/2011 7397 R2214CP  05/13/2011 Pharmacy Billing for Drugs Provided Incident to a Physician Service (This CR rescinds and fully replaces CR 7109)  Rescinded and replaced by Transmittal 2251 06/29/2011 7397 R2115CP  12/10/2010 Pharmacy Billing for Drugs Provided Incident to a Physician
(Medicare Claims Processing Manual)
CR rescinds and fully replaces CR 7109)  Rescinded and replaced by Transmittal 2251 06/29/2011 7397 R2115CP  12/10/2010 Pharmacy Billing for Drugs Provided Incident to a Physician Service  Rescinded and replaced by Transmittal 21214 (CR 7397)  03/14/2011 7109 R2068CP  10/15/2010 Annual Clotting Factor Furnishing Fee Update 2011  01/03/2011 7168 R1962CP  04/30/2010 Discarded Drugs and Biologicals Updates  07/30/2010 6711  Rev #  Issue Date  Subject  Impl Date  CR#  R1908CP  02/05/2010 Clotting Factor Furnishing Fee -Conforming Manual Change to Unit  03/05/2010 6811 R1829CP  10/16/2009 Annual Clotting Factor Furnishing Fee Update  01/04/2010 6673 R1760CP  06/23/2009 July 2009 Update of the Hospital Outpatient Prospective Payment System (OPPS)  07/06/2009 6492 R1745CP  05/22/2009 July 2009 Update of the Hospital Outpatient Prospective Payment System (OPPS) -  Rescinded and replaced by Transmittal 1760  07/06/2009 6492 R1657CP  12/31/2008 January 2009 Update of the Hospital Outpatient Prospective Payment System (OPPS)  01/05/2009 6320 R1653CP  12/19/2008 Annual Clotting Factor Furnishing Fee Update  01/05/2009 6277 R1599CP  09/19/2008 October Update of the Hospital Outpatient Prospective Payment System (OPPS)  10/06/2008 6196 R1581CP  08/29/2008 Discarded Erythropoietin Stimulating Agents for Home Dialysis  12/01/2008 6133 R1564CP  07/25/2008 New Hemophilia Clotting Factor and HCPCS Code  01/05/2009 6006 R1551CP  07/18/2008 New Hemophilia Clotting Factor and HCPCS Code -  Rescinded and replaced by Transmittal 1564 01/05/2009 6006 R1539CP  06/20/200/  Self-Administered Drug Exclusion Lists  07/21/2008 5988 R1513CP  05/23/2008 Average Sales Price
(Medicare Claims Processing Manual)
and replaced by Transmittal 1564 01/05/2009 6006 R1539CP  06/20/200/  Self-Administered Drug Exclusion Lists  07/21/2008 5988 R1513CP  05/23/2008 Average Sales Price Updates  06/23/2008 5798 R1506CP  05/16/2008 Competitive Acquisition Program (CAP): Updating Submission Deadlines for Quarterly Drug List Updates  10/06/2008 6010  Rev #  Issue Date  Subject  Impl Date  CR#  R1478CP  03/14/2008 Additional Clarification to Chapter 17, Section 40, Regarding Processing of Drug Claims with the JW Modifier  04/14/2008 5923 R1472CP  03/06/2008 Update of Institutional Claims References  04/07/2008 5893 R1453CP  02/22/2008 Systems Changes for Prescription Order Numbers for the Competitive Acquisition Program (CAP) for Part B Drugs and Biologicals  07/07/2008 5855 R1448CP  02/15/2008 Adjudicating Claims for Immunosuppressive Drugs When Medicare Did Not Pay for the Original Transplant  07/07/2008 5916 R1445CP  02/08/2008 January 2008 Update of the Hospital Outpatient Prospective Payment System (OPPS) -Manualization  03/10/2008 5946 R1421CP  01/25/2008 Update of Institutional Claims References - Rescinded and Replaced by Transmittal 1472 04/07/2008 5893 R1413CP  01/14/2008 Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions  04/07/2008 5818 R1412CP  01/11/2008 Reporting of Hematocrit or Hemoglobin Levels on All Claims for the Administration of Erythropoiesis Stimulating Agents (ESAs), Implementation of New Modifiers for Non-ESRD Indications, and Reporting of Hematocrit/Hemoglobin Levels on all Non-ESRD, Non -ESA Claims Requesting Payment for Anti -Anemia Drugs  04/07/2008 5699 R1409CP  01/11/2008 Correction to Pub. 100- 04, Chapter 17, Section 100.2.1 02/11/2008 5857 R1357CP  10/26/2007 Payment: Allowances for the Influenza Virus Vaccine and the Pneumococcal Vaccine When Payment is Based
(Medicare Claims Processing Manual)
04, Chapter 17, Section 100.2.1 02/11/2008 5857 R1357CP  10/26/2007 Payment: Allowances for the Influenza Virus Vaccine and the Pneumococcal Vaccine When Payment is Based on 95 11/26/2007 5744  Rev #  Issue Date  Subject  Impl Date  CR#  Percent of the Average Wholesale Price (AWP)  R1338CP  09/21/2007 Medicare Payment for Preadministration Related Services Associated With  IVIG Administration  Payment Extended Through CY 2008 01/07/2008 5713 R1313CP  07/23/2007 Response to Competitive Acquisition for Part B Drugs and Biologicals (CAP) Claims When the Common Working File (CWF) 69XD Error Code is Received  08/23/2007 5658 R1281CP  07/06/2007 Clarification on Billing for Oral Three Drug Combination Anti -Emetic (Aprepitant)  01/07/2008 5655 R1248CP  05/25/2007 Revisions, in the Medicare Claims Processing Manual, to Section 40, titled, "Discarded Drugs and Biologicals," and Section 100.2.9, titled, "Submission of Claims With the Modifier JW, 'Drug Amount Discarded/Not Administered to Any Patient.  07/02/2007 5520 R1212CP  03/30/2007 Requirements for Providing Route of Administration Codes for Erythropoiesis Stimulating Agents (ESAs)  06/29/2007 5480 R1207CP  03/19/2007 Competitive Acquisition Program (CAP) for Part B Drugs  04/19/2007 5546 R1076CP  10/13/2006 Competitive Acquisition Program (CAP)  Instructions on Special CAP Appeals Requirements and Delivery of Dispute Resolution Services  11/13/2006 5207 R1055CP  09/11/2006 Competitive Acquisition Program (CAP) - Creation of Automated Tables for Provider Information, Expansion of CAP Fee Schedule File Layout, and Additional Instructions for Claims Received from Railroad Retirement Board (RRB) Beneficiaries  10/02/2006 5079  Rev #  Issue Date  Subject  Impl Date  CR#  R1034CP  08/18/2006 Competitive Acquisition Program (CAP) - Claim Processing for Not Otherwise Classified ("NOC") Drugs  01/02/2007 5259 R953CP  05/19/2006 CAP -Creation of Automated tables for Providers Information, Expansion of CAP Fee Schedule